Financials data is unavailable for this security.
View more
Year on year Vivimed Labs Ltd 's revenues fell -21.15% from 2.37bn to 1.87bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 676.50m to a larger loss of 3.29bn.
| Gross margin | -62.46% |
|---|---|
| Net profit margin | -214.73% |
| Operating margin | -189.36% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2023, cash reserves at Vivimed Labs Ltd fell by 34.22m. However, the company earned 253.92m from its operations for a Cash Flow Margin of 13.57%. In addition the company generated 49.68m cash from investing, though they paid out 337.82m more in financing than they received.
| Cash flow per share | -25.06 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -385.64%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -297.69 |
